31 May 2025 - mNEXSPIKE becomes Moderna's third FDA approved product.
Moderna today announced that the US FDA has approved mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention.